Floatz logo

Therapeutic Asset Ratings

6,371 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Locally Advanced Rectal Cancer
Institute of Oncology LjubljanaP2BB (66)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Rectal Carcinoma
SWOG Cancer Research NetworkP2BB (66)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Therapy-Related Myelodysplastic Syndrome
M.D. Anderson Cancer CenterP2BB (66)
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Graft Versus Host Disease
Monica BhatiaP2BB (66)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Borderline Resectable Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer InstituteP2BB (66)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer InstituteP2BB (66)
Ipilimumab
Prostate Carcinoma
University Hospital, EssenP2BB (66)
Nivolumab
Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer CenterP2BB (66)
Nivolumab
Refractory Mantle Cell Lymphoma
University of WashingtonP2BB (66)
PANITUMUMAB
Breast Cancer
National Cancer Institute (NCI)P2BB (66)
Pembrolizumab
Acute Lymphoblastic Leukemia
OHSU Knight Cancer InstituteP2BB (66)
Pembrolizumab
B-Cell Non-Hodgkin Lymphoma
Rita AssiP2BB (66)
Pembrolizumab
Diffuse Large B-Cell Lymphoma
Roswell Park Cancer InstituteP2BB (66)
Pembrolizumab
Head And Neck Carcinoma
National Cancer Institute (NCI)P2BB (66)
Pembrolizumab
Metastatic Pancreatic Adenocarcinoma
Mayo ClinicP2BB (66)
Pembrolizumab
Mycosis Fungoides
Sorrento Therapeutics, Inc.P2BB (66)
Pembrolizumab
Non-Hodgkin Lymphoma
Seda S. ToluP2BB (66)
Pembrolizumab
Malignant Pancreatic Neoplasm
Essen BiotechP2BB (66)
Pembrolizumab
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Seda S. ToluP2BB (66)
Pembrolizumab
Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Seda S. ToluP2BB (66)
Pembrolizumab
Urinary Bladder Neoplasm
Eli Lilly and CompanyP2BB (66)
Tislelizumab
Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, ChinaP2BB (66)
Tislelizumab
Acute Myeloid Leukemia With Positive Minimal Residual Disease
Institute of Hematology & Blood Diseases Hospital, ChinaP2BB (66)
Atezolizumab
Fallopian Tube Carcinoma
Ronald BuckanovichP2/3BB (66)
Atezolizumab
Primary Peritoneal Carcinoma
Ronald BuckanovichP2/3BB (66)
Showing 301 to 325 of 6,371 assets
PreviousPage 13 of 255Next